Atriva Therapeutics Starts Clinical Development of novel Host-Targeting Antiviral ATR-002 Against Influenza
- Phase I clinical trial to evaluate safety and tolerability of ATR-002 in healthy volunteers
- ATR-002 expected to show high resilience to viral resistance a Read more ...
A new article has been published by the magazine "Wirtschaftswoche Gründer" about ATRIVA.
Funds to advance antiviral lead product ATR-002 into clinical trials
Tübingen (Germany), January 3, 2019 – Atriva Therapeutics, a biopharmaceutical company pioneering the development of host-targeting antiviral therap